{"id":"https://openalex.org/W4397046265","doi":"https://doi.org/10.1681/asn.20223311s1474a","title":"Effects of Sodium Zirconium Cyclosilicate (SZC) on CKD Progression: Rationale and Design of the Phase 3 STABILIZE-CKD Trial","display_name":"Effects of Sodium Zirconium Cyclosilicate (SZC) on CKD Progression: Rationale and Design of the Phase 3 STABILIZE-CKD Trial","publication_year":2022,"publication_date":"2022-11-01","ids":{"openalex":"https://openalex.org/W4397046265","doi":"https://doi.org/10.1681/asn.20223311s1474a"},"language":"en","primary_location":{"id":"doi:10.1681/asn.20223311s1474a","doi":"https://doi.org/10.1681/asn.20223311s1474a","is_oa":false,"landing_page_url":"https://doi.org/10.1681/asn.20223311s1474a","pdf_url":null,"source":{"id":"https://openalex.org/S115693375","display_name":"Journal of the American Society of Nephrology","issn_l":"1046-6673","issn":["1046-6673","1533-3450"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315620","host_organization_name":"American Society of Nephrology","host_organization_lineage":["https://openalex.org/P4310315620"],"host_organization_lineage_names":["American Society of Nephrology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the American Society of Nephrology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5012514694","display_name":"George L. Bakris","orcid":"https://orcid.org/0000-0003-1183-1267","observed_orcids":["https://orcid.org/0000-0003-1183-1267"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George L. Bakris","raw_affiliation_strings":["University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066841350","display_name":"Kai\u2010Uwe Eckardt","orcid":"https://orcid.org/0000-0003-3823-0920","observed_orcids":["https://orcid.org/0000-0003-3823-0920","https://orcid.org/0000-0001-8345-4371"]},"institutions":[{"id":"https://openalex.org/I181369854","display_name":"Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg","ror":"https://ror.org/00f7hpc57","country_code":"DE","type":"education","lineage":["https://openalex.org/I181369854"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Kai-Uwe Eckardt","raw_affiliation_strings":["University of Erlangen-N\u00fcrnberg, Erlangen-Nuremberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Erlangen-N\u00fcrnberg, Erlangen-Nuremberg, Germany","institution_ids":["https://openalex.org/I181369854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102990856","display_name":"Tom Greene","orcid":"https://orcid.org/0000-0002-0053-485X","observed_orcids":["https://orcid.org/0000-0002-0053-485X"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tom Greene","raw_affiliation_strings":["University of Utah Health Sciences, Salt Lake City, UT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Utah Health Sciences, Salt Lake City, UT","institution_ids":["https://openalex.org/I223532165"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016584401","display_name":"Carol A. Pollock","orcid":"https://orcid.org/0000-0001-7167-6495","observed_orcids":["https://orcid.org/0000-0001-7167-6495"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Carol A. Pollock","raw_affiliation_strings":["University of Sydney, Sydney, NSW, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Sydney, Sydney, NSW, Australia","institution_ids":["https://openalex.org/I129604602"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008309890","display_name":"Robert D. Toto","orcid":"https://orcid.org/0000-0001-9531-1749","observed_orcids":["https://orcid.org/0000-0001-9531-1749"]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert D. Toto","raw_affiliation_strings":["University of Texas Southwestern Medical Center, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas Southwestern Medical Center, Dallas, TX","institution_ids":["https://openalex.org/I867280407"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033996338","display_name":"Matthew R. Weir","orcid":"https://orcid.org/0000-0001-8820-5702","observed_orcids":["https://orcid.org/0000-0001-8820-5702"]},"institutions":[{"id":"https://openalex.org/I126744593","display_name":"University of Maryland, Baltimore","ror":"https://ror.org/04rq5mt64","country_code":"US","type":"education","lineage":["https://openalex.org/I126744593"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew R. Weir","raw_affiliation_strings":["University of Maryland, Baltimore, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Maryland, Baltimore, MD","institution_ids":["https://openalex.org/I126744593"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090228797","display_name":"Ayman Al\u2010Shurbaji","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Ayman Al-shurbaji","raw_affiliation_strings":["AstraZeneca, Gothenburg, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Gothenburg, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025170201","display_name":"Nicolas Jose Guzman","orcid":"https://orcid.org/0000-0002-9503-0530","observed_orcids":["https://orcid.org/0000-0002-9503-0530"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicolas J. Guzman","raw_affiliation_strings":["AstraZeneca, Gaithersburg, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Gaithersburg, MD","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072606371","display_name":"Vera Lisovskaja","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Vera Lisovskaja","raw_affiliation_strings":["AstraZeneca, Gothenburg, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Gothenburg, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054815299","display_name":"Peter Wessman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Peter Wessman","raw_affiliation_strings":["AstraZeneca, Gothenburg, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Gothenburg, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112754141","display_name":"Yanli Zhao","orcid":"https://orcid.org/0000-0002-9231-8360","observed_orcids":["https://orcid.org/0000-0002-9231-8360"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yanli Zhao","raw_affiliation_strings":["AstraZeneca, Gaithersburg, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Gaithersburg, MD","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5034939991","display_name":"Glenn Matthew Chertow","orcid":"https://orcid.org/0000-0002-7599-0534","observed_orcids":["https://orcid.org/0000-0002-7599-0534"]},"institutions":[{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Glenn Chertow","raw_affiliation_strings":["Stanford University, Stanford, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford University, Stanford, CA","institution_ids":["https://openalex.org/I97018004"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"33","issue":"11S","first_page":"474","last_page":"474"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12876","display_name":"Potassium and Related Disorders","score":0.7348999977111816,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12876","display_name":"Potassium and Related Disorders","score":0.7348999977111816,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.23569999635219574,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.0035000001080334187,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sodium-zirconium-cyclosilicate","display_name":"sodium zirconium cyclosilicate","score":1.0},{"id":"https://openalex.org/keywords/chronic-kidney-disease-progression","display_name":"chronic kidney disease progression","score":0.9789999723434448},{"id":"https://openalex.org/keywords/hyperkalemia","display_name":"hyperkalemia","score":0.9919999837875366},{"id":"https://openalex.org/keywords/ace-inhibitors","display_name":"ACE inhibitors","score":0.8059999942779541},{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.9990000128746033},{"id":"https://openalex.org/keywords/lisinopril","display_name":"lisinopril","score":0.9419999718666077},{"id":"https://openalex.org/keywords/valsartan","display_name":"valsartan","score":1.0},{"id":"https://openalex.org/keywords/renal-protection","display_name":"renal protection","score":0.9419999718666077},{"id":"https://openalex.org/keywords/estimated-glomerular-filtration-rate","display_name":"estimated glomerular filtration rate","score":0.8360000252723694},{"id":"https://openalex.org/keywords/potassium-binding-agents","display_name":"potassium-binding agents","score":0.33799999952316284}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5427650809288025},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.49545514583587646},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.43719664216041565},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.41335737705230713},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.40430232882499695},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.27093344926834106},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1681/asn.20223311s1474a","doi":"https://doi.org/10.1681/asn.20223311s1474a","is_oa":false,"landing_page_url":"https://doi.org/10.1681/asn.20223311s1474a","pdf_url":null,"source":{"id":"https://openalex.org/S115693375","display_name":"Journal of the American Society of Nephrology","issn_l":"1046-6673","issn":["1046-6673","1533-3450"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315620","host_organization_name":"American Society of Nephrology","host_organization_lineage":["https://openalex.org/P4310315620"],"host_organization_lineage_names":["American Society of Nephrology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the American Society of Nephrology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4413109079","https://openalex.org/W7222215884","https://openalex.org/W3005302717","https://openalex.org/W4403831051","https://openalex.org/W3180210435","https://openalex.org/W4398756109","https://openalex.org/W2803374051","https://openalex.org/W4397045420","https://openalex.org/W4415164474","https://openalex.org/W7128079523"],"abstract_inverted_index":{"Background:":[0],"Patients":[1],"with":[2,60,79,106,153,227,231],"CKD":[3,56,80,87,222],"who":[4],"may":[5],"benefit":[6],"from":[7,168,176],"angiotensin-converting":[8],"enzyme":[9],"inhibitor":[10],"(ACEi)":[11],"or":[12,20,33,62,86,97,115,135,144,197,229,233],"angiotensin":[13],"receptor":[14],"blocker":[15],"(ARB)":[16],"therapy":[17,25,93,117],"frequently":[18],"discontinue":[19],"do":[21,38],"not":[22,39],"receive":[23],"ACEi/ARB":[24,52,84,92,109],"at":[26],"recommended":[27],"doses":[28,123],"due":[29,94],"to":[30,95,121,148,170,181,187,194],"hyperkalemia":[31],"(HK)":[32],"HK":[34,61,64,82,96,99,232,235],"risk,":[35],"and":[36,54,81,88,142,175,192,202],"thus":[37],"experience":[40],"maximal":[41],"renoprotection.":[42],"We":[43],"hypothesize":[44],"that":[45],"SZC,":[46],"an":[47,208],"oral":[48],"anti-hyperkalemic,":[49],"will":[50,118,131,204,217],"enable":[51],"optimization":[53],"slow":[55],"progression":[57,223],"in":[58,224],"patients":[59,78,130,225],"high":[63,98,234],"risk.":[65,236],"Methods:":[66],"This":[67],"Phase":[68],"3,":[69],"international,":[70],"randomized":[71,140],"withdrawal,":[72],"parallel-group":[73],"trial":[74],"is":[75],"enrolling":[76],"adult":[77],"on":[83,90],"therapy,":[85],"normokalemia":[89,105],"limited/no":[91],"risk":[100],"(NCT05056727;":[101],"Figure).":[102],"After":[103],"establishing":[104],"SZC":[107,126,134,220],"(without":[108],"dose":[110,199],"change;":[111],"initiation":[112],"phase),":[113,128,152],"lisinopril":[114,143,196],"valsartan":[116,145,198],"be":[119,132,205],"up-titrated":[120],"guideline-recommended":[122],"while":[124],"continuing":[125],"(run-in":[127],"then":[129],"administered":[133],"placebo":[136],"(in":[137],"a":[138,188],"double-blind":[139],"fashion)":[141],"for":[146],"up":[147],"24":[149],"months":[150],"(maintenance":[151],"repeated":[154],"estimated":[155],"glomerular":[156],"filtration":[157],"rate":[158],"(eGFR)":[159],"measurements.":[160],"Results:":[161],"The":[162,214],"primary":[163],"endpoints":[164,184],"are":[165],"eGFR":[166],"measures":[167],"randomization":[169,180],"end":[171],"of":[172],"study":[173,216],"(EOS)":[174],"12":[177],"weeks":[178],"after":[179],"EOS.":[182],"Secondary":[183],"include":[185],"time":[186,193],"kidney":[189],"composite":[190],"endpoint":[191],"first":[195],"decrease.":[200],"Safety":[201],"tolerability":[203],"assessed":[206],"by":[207],"independent":[209],"data":[210],"monitoring":[211],"committee.":[212],"Conclusions:":[213],"STABILIZE-CKD":[215],"assess":[218],"if":[219],"attenuates":[221],"treated":[226],"ACEi":[228],"ARB":[230],"Funding:":[237],"Commercial":[238],"Support":[239],"-":[240],"AstraZenecaStudy":[241],"Design":[242]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2024-05-19T00:00:00"}